No Data
Biomedical stocks are performing strongly. Lai Kai Medicine (02105) rose by 26.26%, institutions pointed out that the sector's valuation has reached a historical low, still with further room for recovery.
Golden Finance News | Biomedical stocks are strong, with LaiKai Pharmaceutical (02105) up 26.26%, AmyMed Vaccine (06660) up 19.76%, YimingAngke (01541) up 7.04%, Hansoh Pharma (03692) up 6.4%, Hutchmed (China) (00013) up 6.91%, Peijia Medical (09996) up 5.75%, Akeso (09926) up 5.77%. Bocom Intl stated that the tenth batch of National Drug Centralized Procurement Volume Document shows the highest historical threshold for this round of national procurement, the highest proportion of injections in history, and expects the competition to be exceptionally fierce, but for
Express News | ImmuneOnco Biopharmaceuticals Shanghai Inc - Resolved to Nominate Zhang Ruliang as an Executive Director
Trending Industry Today: CHINA VANKE Leads Gains In Top Gainers Yesterday Stocks
Emperor Entertainment Hotel Limited (01541) nominated Mr. Fu Tai-Yat as a non-executive director.
Yiming Angco-B (01541) announced that Mr. Xiaoyong has submitted his resignation as a non-executive director of the company, effective 2024...
Pacific Securities initiated coverage on Immunotech (01541) with a "buy" rating, indicating that the peak sales of its two dual-specificity antibodies are expected to reach 3.17 billion yuan.
King's Financial News | Pacific Securities Research Report indicates that Yimingonc (01541) subsidiary IMM0306 is conducting the Ib/II phase clinical trial: In January 2023, NMPA approved IMM0306 in combination with lenalidomide for Ib/IIa clinical trial application, for front-line treatment of B-cell non-Hodgkin's lymphoma (B-NHL), with the first patient dosed in June 2023. As of June 30, 2024, among 11 evaluable patients, ORR was 90.9%, CR was 27.3%. Currently, the indication for R/RB-NHL is in Phase Ib/II clinical research.
Express News | ImmuneOnco Biopharmaceuticals Shanghai Inc - Subscribe for a Wealth Management Product in Amount of HK$200 Mln From Haitong ASM
No Data
No Data